Chakkour K, Gouny P, Nussaume O, Vayssairat M
Service de Chirurgie Vasculaire et Thoracique, Hôpital Rothschild, Paris.
J Mal Vasc. 1995;20(4):288-9.
There is no known treatment capable of avoiding extension and rupture of aneurysms of the abdominal aorta. There has however been much work recently suggesting a favourable effect of beta-blockers. Early work with experimental animal models of aortic aneurysms showed that Propranolol has a protective effect on extension and rupture of these aneurysms. Studies of the biochemistry of the aortic wall have shown that Propranolol has an independent effect on blood pressure, stimulation lysyl-oxidase and production of intermolecular elastin bridges which strengthen the arterial wall. In man, Propranolol slows the progressive dilatation of the aorta in Marfan's disease. These data on atherosclerosis aneurysms are only part of the picture, but 3 studies have shown that slower widening of the aorta diameter is related to treatment with beta-blockers. In conclusion, the surgical indications for aneurysms in 1995 are unchanged from those in 1994. In cases where surgery is not indicated (patient refusal, operative risk too high, small aneurysms) could comprise a study group for a randomized evaluation against placebo of the effect of beta-blockers. A controlled study is required before therapeutic strategies can be modified.
目前尚无已知的治疗方法能够避免腹主动脉瘤的扩展和破裂。然而,最近有许多研究表明β受体阻滞剂具有有益作用。早期对主动脉瘤实验动物模型的研究表明,普萘洛尔对这些动脉瘤的扩展和破裂具有保护作用。对主动脉壁生物化学的研究表明,普萘洛尔对血压具有独立作用,可刺激赖氨酰氧化酶并产生分子间弹性蛋白桥,从而增强动脉壁。在人类中,普萘洛尔可减缓马凡氏综合征患者主动脉的渐进性扩张。这些关于动脉粥样硬化性动脉瘤的数据只是部分情况,但有3项研究表明,主动脉直径增宽较慢与β受体阻滞剂治疗有关。总之,1995年动脉瘤的手术指征与1994年相同。在不适合手术的情况下(患者拒绝、手术风险过高、动脉瘤较小),可以组成一个研究组,针对β受体阻滞剂与安慰剂作用效果进行随机评估。在修改治疗策略之前,需要进行对照研究。